India Groups Unite To Challenge Herceptin Breast Cancer Patent (India)
This article was originally published in PharmAsia News
Executive SummaryGroups in India are organizing to challenge the patent granted F. Hoffman-LaRoche for its Herceptin (trastuzumb) for fighting breast cancer. The challengers have formed the Lawyers Collective to fight for women's issues, arguing in this case that giving the drug patent protection denies millions of women with the cancer from having access to cheap versions. The same group challenged a Novartis application for a patent on its Gleevec (imatinib mesylate) in 2005, and litigation continues. (Click here for more
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.